JP2015000064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015000064A5 JP2015000064A5 JP2014123573A JP2014123573A JP2015000064A5 JP 2015000064 A5 JP2015000064 A5 JP 2015000064A5 JP 2014123573 A JP2014123573 A JP 2014123573A JP 2014123573 A JP2014123573 A JP 2014123573A JP 2015000064 A5 JP2015000064 A5 JP 2015000064A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- hematopoietic stem
- bone marrow
- progenitor cells
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims 7
- 208000014905 bone marrow failure syndrome Diseases 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 210000000130 stem cell Anatomy 0.000 claims 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/919,241 | 2013-06-17 | ||
| US13/919,241 US9428748B2 (en) | 2013-06-17 | 2013-06-17 | Method of expanding hematopoietic stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015000064A JP2015000064A (ja) | 2015-01-05 |
| JP2015000064A5 true JP2015000064A5 (enExample) | 2017-08-03 |
| JP6532653B2 JP6532653B2 (ja) | 2019-06-19 |
Family
ID=50942591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014123573A Active JP6532653B2 (ja) | 2013-06-17 | 2014-06-16 | 造血幹細胞の増殖方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9428748B2 (enExample) |
| EP (1) | EP2816107B1 (enExample) |
| JP (1) | JP6532653B2 (enExample) |
| DK (1) | DK2816107T3 (enExample) |
| ES (1) | ES2757508T3 (enExample) |
| HU (1) | HUE046356T2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136322A1 (en) * | 2016-02-04 | 2017-08-10 | Zhenglun Zhu | Treatment and diagnosis of inflammatory disorders |
| GB201608944D0 (en) * | 2016-05-20 | 2016-07-06 | Ospedale San Raffaele And Fond Telethon | Gene Tharapy |
| US20230279440A1 (en) | 2020-05-06 | 2023-09-07 | Cellectis S.A. | Methods to genetically modify cells for delivery of therapeutic proteins |
| WO2021224395A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5908779A (en) | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| CA2386192A1 (en) * | 1999-10-07 | 2001-04-12 | Avi Biopharma, Inc. | C-myc antisense-treated hematopoietic stem cell composition and method |
| KR20050115231A (ko) * | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
| CA2517959A1 (en) * | 2003-03-07 | 2004-09-16 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
| EP1991246B1 (en) | 2006-02-22 | 2013-09-11 | Zhenglun Zhu | Treatment of development-related disorders |
| CN101495623B (zh) * | 2006-03-24 | 2013-09-11 | 儿童医疗中心有限公司 | 调节造血干细胞生长的方法 |
| WO2011008947A2 (en) * | 2009-07-15 | 2011-01-20 | Zhenglun Zhu | Treatment and diagnosis of immune disorders |
| WO2011028819A1 (en) * | 2009-09-01 | 2011-03-10 | The Trustees Of Columbia University In The City Of New York | Synergistic transcription modules and uses thereof |
| US8741640B2 (en) * | 2010-11-24 | 2014-06-03 | Hong Gao | Expanding hematopoietic stem cells |
| WO2012170979A1 (en) | 2011-06-10 | 2012-12-13 | Zhenglun Zhu | Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof |
| CA2848359A1 (en) * | 2011-09-11 | 2013-03-14 | Aurasense, Llc | Cellular uptake control systems |
| EP2984165B1 (en) * | 2013-04-10 | 2020-12-23 | Zhenglun Zhu | Homeobox transcription factor ventx regulates differentiation and maturation of human dendritic cells |
-
2013
- 2013-06-17 US US13/919,241 patent/US9428748B2/en active Active
-
2014
- 2014-06-16 ES ES14172624T patent/ES2757508T3/es active Active
- 2014-06-16 DK DK14172624T patent/DK2816107T3/da active
- 2014-06-16 JP JP2014123573A patent/JP6532653B2/ja active Active
- 2014-06-16 EP EP14172624.0A patent/EP2816107B1/en active Active
- 2014-06-16 HU HUE14172624A patent/HUE046356T2/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| MX384315B (es) | Agente para el tratamiento y/o prevención de enfermedades asociadas con anormalidades inmunes. | |
| BR112017014269A2 (pt) | células exterminadoras naturais e usos das mesmas | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| JP2014240404A5 (enExample) | ||
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| NZ739448A (en) | Transgene genetic tags and methods of use | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| JP2014169326A5 (enExample) | ||
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| JP2018522041A5 (enExample) | ||
| HRP20240798T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| JP2015000064A5 (enExample) | ||
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| WO2014152754A3 (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | |
| BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| JP2015517520A5 (enExample) | ||
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| CY1122042T1 (el) | Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο | |
| JP2016515123A5 (enExample) | ||
| CL2018002438A1 (es) | Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna. | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| WO2016066722A3 (en) | Bacteriophage combinations for human or animal therapy | |
| BR112017002212A2 (pt) | peptídeo derivado de cdca1 e vacina contendo o mesmo | |
| JP2015174843A5 (enExample) |